Corrigendum: Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis

Corrigendum: Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis

Bibliographic Details
Main Authors:	Qiang Zhang, Hua Zhong, Yinchun Fan, Qian Liu, Jiancheng Song, Shengtao Yao, Fang Cao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-10-01
Series:	Frontiers in Bioengineering and Biotechnology
Subjects:	CD96 glioma immune checkpoint prognosis immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fbioe.2020.599544/full

Similar Items

Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis
by: Qiang Zhang, et al.
Published: (2020-06-01)

Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma
by: Shasha Liu, et al.
Published: (2019-07-01)

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity
by: Amelia Roman Aguilera, et al.
Published: (2018-05-01)

CD48 is a key molecule of immunomodulation affecting prognosis in glioma
by: Zou C, et al.
Published: (2019-05-01)

Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
by: Yongliang Yuan, et al.
Published: (2019-07-01)

CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis
by: Wenrui Ye, et al.
Published: (2021-02-01)

Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma
by: Chaoqi Zhang, et al.
Published: (2018-11-01)

Immunotherapy with heat shock protein 96 to treat gliomas
by: Chunzhao Li, et al.
Published: (2020-09-01)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
by: Amina Ghouzlani, et al.
Published: (2021-07-01)

CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas
by: Shengchao Xu, et al.
Published: (2021-09-01)

Coming of Age: CD96 Emerges as Modulator of Immune Responses
by: Hristo Georgiev, et al.
Published: (2018-05-01)

Specific clinical and immune features of CD68 in glioma via 1,024 samples
by: Wang L, et al.
Published: (2018-11-01)

A novel gene signature based on five immune checkpoint genes predicts the survival of glioma
by: Wei Zhang, et al.
Published: (2021-02-01)

Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions
by: Lynn Bitar, et al.
Published: (2021-07-01)

CTLA-4 correlates with immune and clinical characteristics of glioma
by: Fangkun Liu, et al.
Published: (2020-01-01)

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas
by: Zenghui Qian, et al.
Published: (2018-06-01)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
by: Ralph Ja Maas, et al.
Published: (2020-01-01)

The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
by: Taofei Zeng, et al.
Published: (2021-09-01)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
by: Depei Li, et al.
Published: (2021-03-01)

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
by: Yangzhi Qi, et al.
Published: (2020-11-01)

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis
by: Heidi Harjunpää, et al.
Published: (2018-07-01)

PD-1 related transcriptome profile and clinical outcome in diffuse gliomas
by: Shuai Liu, et al.
Published: (2018-02-01)

Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma
by: Alexandra Foster, et al.
Published: (2021-09-01)

Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy
by: Haidar H Al-Fatlawi, et al.
Published: (2016-01-01)

Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment
by: Nan Zhang, et al.
Published: (2021-08-01)

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma
by: Zaoqu Liu, et al.
Published: (2021-07-01)

Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
by: Huaide Qiu, et al.
Published: (2021-04-01)

Construction of a prognostic immune signature for lower grade glioma that can be recognized by MRI radiomics features to predict survival in LGG patients
by: Zi-zhuo Li, et al.
Published: (2021-06-01)

A Focal Adhesion-Related Gene Signature Predicts Prognosis in Glioma and Correlates With Radiation Response and Immune Microenvironment
by: Haonan Li, et al.
Published: (2021-09-01)

Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy
by: Quan Cheng, et al.
Published: (2021-07-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
by: Xiaohan Zhou, et al.
Published: (2021-07-01)

Development of a prognostic index based on immunogenomic landscape analysis in glioma
by: Haitao Luo, et al.
Published: (2021-06-01)

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
by: Li GZ, et al.
Published: (2019-11-01)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021-02-01)

Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01)

Expression and Significance of gp96 and Immune-related Gene CTLA-4, CD8 in Lung Cancer Tissues
by: Haiyan ZHENG, et al.
Published: (2010-08-01)

Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives
by: Pasquale Persico, et al.
Published: (2021-03-01)

Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis
by: Yao Jin, et al.
Published: (2021-06-01)

Immunotherapy is expected to be the ultimate nemesis of malignant glioma
by: Xue⁃jun YANG
Published: (2020-02-01)